Pathomation and Mindpeak Forge Strategic Partnership to Accelerate AI Adoption in Digital Pathology Workflows
Pathomation and Mindpeak: Mindpeak’s CE-IVD certified algorithms are now fully integrated and operational within Pathomation’s trusted digital pathology platform, built for interoperability and control, enabling frictionless AI adoption in pathology workflows.
Antwerp, Belgium – August 2025, Pathomation proudly announces a strategic partnership with Mindpeak, the pioneering provider of CE-IVD certified AI solutions for tissue image analysis. The collaboration ensures full technical compatibility between Mindpeak’s state-of-the art algorithms and Pathomation’s software ecosystem, enabling pathology labs to seamlessly integrate AI to improve existing workflows.
Through this partnership, Mindpeak’s CE-IVD certified algorithms including Ki-67, HER2, and “0-click” PD-L1 scoring across multiple tissue types (lung, bladder, gastric, breast, and esophagus), can now be deployed directly within Pathomation’s modular software components. “Having personal experience training pathologists on new biomarkers, I am convinced that reducing the complexity and time investment of quantitative PD-L1 and HER2 scoring will be a relief to Pathologists.” said Rudy Hovelinck, CEO of Pathomation “The direct AI marketplace integration in the PIMSDX software is an additional boost for anyone that wants to start using AI algorithms in clinical routine without custom developments.” The AI marketplace is intended to give labs maximum control over where and how they use AI, and enables AI use in the Pathomation clinical diagnostics, research, and for training Digital Pathology applications.
This partnership is another milestone in our mission to make AI adoption effortless for pathology labs,” said Felix Faber, CEO of Mindpeak added. “By embedding our CE-IVD certified algorithms directly into Pathomation’s interoperable platform, we’re removing technical and operational barriers, ensuring that pathologists can seamlessly access our cutting-edge AI tools where they work every day.
Pathomation’s architecture is designed to adapt to any lab’s needs, built for interoperability, security, and full customization to fit each customer’s workflow. Combined with Mindpeak’s best-in-class algorithms, this partnership marks a significant step forward in accelerating AI adoption across labs worldwide.
About Pathomation
Pathomation is a Digital Pathology software developer and manufacturer, located in Antwerp, Belgium. Pathomation commercializes products for Educational, Research and Diagnostic IVD use and provides custom development and expert project services for OEM companies and the pharmaceutical sector. Pathomation is active in the promotion, marketing and commercialization of its products to end users, direct or through distributors, around the globe and provides scientific and technical support.
Pathomation’s digital pathology software solutions reduce laboratory expenses,
boost operational efficiency, enhance productivity, aid in better treatment decisions
and ultimately improve patient care.
Visit our website www.pathomation.com and follow us on LinkedIn for more information.
Press contact: info@pathomation.com
About Mindpeak
Mindpeak is the leading company in AI-powered digital pathology, bridging the gap from biomarker development to clinical diagnostics. Founded in 2018, Mindpeak’s AI technology enables laboratories to extract actionable insights from H&E, IHC and mIF tissue images – ranging from subcellular biomarker quantification to predictive patient stratification. The solutions support both routine diagnostics and the translation of novel biomarkers into real-world clinical applications.
For more information, visit www.mindpeak.ai or follow us on LinkedIn.
SOURCE: Pathomation
